Published in Blood Weekly, April 19th, 2001
"Thrombocytopenia following myelotoxic therapy is a common problem and, when severe (< 20,000/(mu)/l), can lead to severe morbidity and mortality," S.N. Wolff and colleagues wrote in the journal Bone Marrow Transplantation.
Wolff et al. found that rhTPO - the recombinant form of a peptide that stimulates megakaryocyte proliferation and differentiation - safely promoted fast platelet recovery after autologous bone marrow transplantation and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.